Literature DB >> 23946137

A systematic approach to emergent breast free flap takeback: Clinical outcomes, algorithm, and review of the literature.

Ibrahim Khansa1, Albert H Chao2, Maakan Taghizadeh2, Theodore Nagel2, Duane Wang2, Pankaj Tiwari2.   

Abstract

BACKGROUND: Few evidence-based and detailed algorithms exist on the management of failing breast free flaps, including use of the numerous salvage tools that are available. The purpose of this study was to analyze our outcomes with an algorithmic approach to breast free flap salvage after vascular compromise. A review of the literature is also presented.
METHODS: A retrospective review of all breast free flaps performed at our institution between 2007 and 2012 was performed. Flaps with intraoperative and postoperative vascular complications were analyzed.
RESULTS: A total of 612 microsurgical breast reconstructions in 442 patients were reviewed. Of these, 72 (11.8%) flaps had intraoperative vascular complications, and 36 (5.9%) had postoperative vascular complications. The total flap loss rate was 2.8%. The most commonly used salvage modalities were anastomotic revision (72%), heparin irrigation (72%), systemic heparin (37%), Fogarty catheter thrombectomy (17.6%), thrombolytics (13%), and indocyanine green angiography (10.2%). In 53 (49.1%) cases, flap salvage involved use of 1 modality, whereas in 55 (50.9%) cases multiple modalities were used. Factors associated with failure of these flap salvage tools included intraoperative arterial rather than postoperative arterial compromise (P = 0.01), and situations requiring use of a greater number of salvage modalities (P < 0.001).
CONCLUSIONS: We found that intraoperative compromise had significantly better prognosis than postoperative compromise. By organizing the numerous salvage modalities available to microsurgeons into a well-defined algorithm that is supported by the literature, we have established a best practices protocol that has achieved flap salvage rates that compare favorably to the published literature.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23946137     DOI: 10.1002/micr.22151

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  6 in total

Review 1.  Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.

Authors:  Rajiv P Parikh; Elizabeth B Odom; Liyang Yu; Graham A Colditz; Terence M Myckatyn
Journal:  Breast Cancer Res Treat       Date:  2017-02-09       Impact factor: 4.872

Review 2.  Free Tissue Breast Reconstruction.

Authors:  Rami Dibbs; Jeff Trost; Valerie DeGregorio; Shayan Izaddoost
Journal:  Semin Plast Surg       Date:  2019-03-08       Impact factor: 2.314

Review 3.  Management of postoperative microvascular compromise and ischemia reperfusion injury in breast reconstruction using autologous tissue transfer: Retrospective review of 2103 flaps.

Authors:  Michelle Coriddi; Paige Myers; Babak Mehrara; Jonas Nelson; Peter G Cordeiro; Joseph Disa; Evan Matros; Joseph Dayan; Robert Allen; Colleen McCarthy
Journal:  Microsurgery       Date:  2021-12-02       Impact factor: 2.425

4.  Anterograde Injection of Alteplase Salvages Deep Inferior Epigastric Perforator Flap in Reconstructive Breast Surgery.

Authors:  Julia M Wimbauer; Klemens M Heinrich; Karl Schwaiger; Peter Pumberger; Fabian Koeninger; Gottfried Wechselberger; Elisabeth Russe
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-06-20

5.  Successful Salvage of Delayed Venous Congestion After DIEP Flap Breast Reconstruction.

Authors:  Kristopher Katira; Samita Goyal; Chelsea Venditto; John A LoGiudice; Erin L Doren
Journal:  Eplasty       Date:  2019-12-03

6.  Indocyanine Green Angiography in Breast Reconstruction: Utility, Limitations, and Search for Standardization.

Authors:  Ariel C Johnson; Salih Colakoglu; Tae W Chong; David W Mathes
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.